Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.44 |
| ▸ | PDE1A | P54750 | 2/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13533471 | 0.86 | PDE5A (0.49) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3175238 | 0.83 | PDE4A (0.43) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3123904 | 0.82 | ADORA2A (0.46) | PDE4APDE4BPDE4CPDE4DADORA1 | |
| SCHEMBL3175170 | 0.82 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL1808708 | 0.81 | PDE1A (0.48) | PDE2APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL3181178 | 0.80 | ADORA2A (0.54) | PDE2APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL3119502 | 0.80 | ADORA1 (0.47) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3175131 | 0.80 | PDE4A (0.57) | PDE2APDE1APDE1BPDE1CPDE4A | |
| SCHEMBL3185628 | 0.78 | ADORA1 (0.48) | PDE4APDE4BPDE4CPDE4DADORA1 | |
| SCHEMBL19583228 | 0.78 | PDE1A (0.56) | PDE2APDE1APDE1BPDE1CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251675-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Co., Ltd. (CN) | 2017-12-06 | — | — | EP | claimed |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Pte. Ltd. (SG) | 2017-11-16 | — | — | US | claimed |
| EP-3251675-B1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | SHANTON PHARMA PTE LTD (SG) | 2021-04-21 | — | — | EP | disclosed |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | SHANTON PHARMA CO., LTD (CN) | 2019-06-18 | — | — | US | disclosed |
| EP-3251675-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Co., Ltd. (CN) | 2017-12-06 | — | — | EP | disclosed |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Pte. Ltd. (SG) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | NLRP3, REN, SLC5A1 | PDE2A 2077/4885PDE1A 4787/4885PDE1B 4808/4885 |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | REN, NLRP3, SLC5A1 | PDE2A 2454/4885PDE1A 4751/4885PDE1B 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.